Multivalent N -Acetylgalactosamine-Conjugated siRNA Localizes in Hepatocytes and Elicits Robust RNAi-Mediated Gene Silencing
Alnylam Pharmaceuticals (United States) · Centre for Human Drug Research · +1 more institution
Abstract
Conjugation of small interfering RNA (siRNA) to an asialoglycoprotein receptor ligand derived from N-acetylgalactosamine (GalNAc) facilitates targeted delivery of the siRNA to hepatocytes in vitro and in vivo. The ligands derived from GalNAc are compatible with solid-phase oligonucleotide synthesis and deprotection conditions, with synthesis yields comparable to those of standard oligonucleotides. Subcutaneous (SC) administration of siRNA-GalNAc conjugates resulted in robust RNAi-mediated gene silencing in liver. Refinement of the siRNA chemistry achieved a 5-fold improvement in efficacy over the parent design in vivo with a median effective dose (ED50) of 1 mg/kg following a single dose. This enabled the SC…
Citation impact
- FWCI
- 27.31
- Percentile
- 100%
- References
- 38
Authors
25- JKJayaprakash K. NairCorresponding
Alnylam Pharmaceuticals (United States)
- JLJennifer L. S. Willoughby
Alnylam Pharmaceuticals (United States)
- ACAmy Chan
Alnylam Pharmaceuticals (United States)
- KCKlaus Charissé
Alnylam Pharmaceuticals (United States)
- MRMd. Rowshon Alam
Alnylam Pharmaceuticals (United States)
Topics & keywords
- Gene silencing
- RNA interference
- Small interfering RNA
- Chemistry
- Asialoglycoprotein receptor
- In vivo
- Oligonucleotide
- In vitro
- Good health and well-being